Gould I M
Department of Medical Microbiology, Aberdeen Royal Infirmary, Foresterhill, Aberdeen AB25 2ZN, UK.
Int J Antimicrob Agents. 2006 Nov;28(5):379-84. doi: 10.1016/j.ijantimicag.2006.09.001. Epub 2006 Oct 11.
For most countries badly affected by methicillin-resistant Staphylococcus aureus (MRSA) there have been many years of debate about its relative virulence compared with methicillin-susceptible S. aureus (MSSA) and whether it could be controlled. Now that it is endemic in the majority of hospitals around the world, it is clear that it is at least as virulent as MSSA and is an additional burden of healthcare-acquired infection. There is increasing evidence that, despite this endemicity, control efforts can be successful, although they are often perceived as expensive. In reality, there is a large body of consistent evidence that control is highly cost effective, particularly in the context of the huge societal costs of MRSA and the future ever-greater threats that it poses.
对于大多数受耐甲氧西林金黄色葡萄球菌（MRSA）严重影响的国家而言，多年来一直存在关于MRSA与甲氧西林敏感金黄色葡萄球菌（MSSA）相比的相对毒力以及它是否能够得到控制的争论。如今它在全球大多数医院中呈地方性流行，很明显它至少与MSSA一样具有毒力，并且是医疗保健相关感染的额外负担。越来越多的证据表明，尽管存在这种地方性流行，但控制措施仍可取得成功，尽管这些措施通常被认为成本高昂。实际上，有大量一致的证据表明控制措施具有很高的成本效益，特别是考虑到MRSA带来的巨大社会成本以及它未来构成的更大威胁。
